Read full story

P.F. Chang’s 34-year-old CEO on what he learned from billionaire John Paulson

Read full story

Target boycott may be a ‘really important case’ for retailers who experience backlash

Read full story

AI on game day: Pro sports franchises are turning to the tech for everything from concession stands to statistics

Read full story

What Google, Martha Stewart, Amazon and others have gotten so wrong about the remote-work debate

Read full story

As the Equal Pay Act turns 60, ‘an uneven playing field’ remains. Here’s where pay equity stands.

Read full story

FDA advisers vote in favor of Biogen and Eisai’s collaborative Alzheimer’s treatment

LATEST PODCAST 开奖记录下载|幸运飞行艇官方开奖直播结果

Partner Center


Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

  • Symbol Last Change Chg Change % Chg % Volume
No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

Create a list of the investments you want to track.

Uh oh

Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval

Biogen Inc. BIIB shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and Drug Administration advisory committee to approve an Alzheimer’s treatment it makes with Eisai Co. ESALF Biogen shares rallied as much as 9% after hours, after spending the regular session halted at $308.88. Eisai shares finished Friday up 9.4% at $81.03. On Friday, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously to recommend the companies’ drug Leqembi to treat Alzheimer’s disease. While the FDA is not bound to committee recommendations, the agency generally follows them. Approval of the drug is expected by July 6.

Specialty-chemicals maker Chase Corp. looking to sell itself: WSJ

Shares of Chase Corp. CCF rallied more than 5% in the extended session Friday after The Wall Street Journal reported that the specialty-chemicals maker is working with advisers on a potential sale. According to the report, which cited people familiar with the matter, Chase has received multiple bids from private-equity firms and other industrial companies. One of the private-equity bids comes from Pritzker Private Capital, the report said. Pritzker Private Capital is a family-owned investment firm connected to the family of Illinois Gov. J.B. Pritzker and others. Chase Corp.’s market capitalization hovered at around $1.17 billion, according to FactSet as of late Friday. The stock has gained about 43% so far this year, compared with an advance of around 12% for the S&P 500 index. SPX

Turo’s quarterly revenue rose 30%, but losses widened, car-sharing company says in IPO filing tweak

Car-sharing company Turo late Friday updated its initial public offering filing, saying that revenue rose 30% to $186 million in first quarter, from $143 million in the year-ago period. That also compares with $747 million in revenue for all of 2022. Losses widened, however, to $24.3 million, or 76 cents a share, in the quarter, from $7 million, or 23 cents a share, a year ago. Turo, which publicly filed for its IPO in January 2022, said that as of March 31 it had more than 165,000 active “hosts,” or people and small businesses using the platform to rent their vehicles. “Many of our small business and professional hosts started their journey with us as consumer hosts and scaled their businesses as they saw success on our platform,” the company said. More than 3 million “guests,” or those who rented the cars, booked more than 19.1 million days on Turo’s platform in all of last year, the company said.

Small-cap ETFs may look attractive as recession concerns fade, but blindly chasing the rally is not without risk